Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Equity Average (2016 - 2025)

Historic Equity Average for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $880.3 million.

  • Haemonetics' Equity Average fell 140.49% to $880.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $880.3 million, marking a year-over-year decrease of 140.49%. This contributed to the annual value of $890.4 million for FY2025, which is 15.97% up from last year.
  • Latest data reveals that Haemonetics reported Equity Average of $880.3 million as of Q4 2025, which was down 140.49% from $865.7 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Equity Average peaked at $951.6 million during Q1 2024, and registered a low of $687.8 million during Q4 2021.
  • For the 5-year period, Haemonetics' Equity Average averaged around $820.1 million, with its median value being $846.4 million (2023).
  • In the last 5 years, Haemonetics' Equity Average surged by 2488.9% in 2021 and then plummeted by 922.52% in 2025.
  • Over the past 5 years, Haemonetics' Equity Average (Quarter) stood at $687.8 million in 2021, then rose by 9.4% to $752.5 million in 2022, then grew by 22.06% to $918.5 million in 2023, then dropped by 2.79% to $892.9 million in 2024, then decreased by 1.4% to $880.3 million in 2025.
  • Its last three reported values are $880.3 million in Q4 2025, $865.7 million for Q3 2025, and $851.6 million during Q2 2025.